TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06209801

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: 60 seconds of intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: 60 seconds of intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: 60 seconds of intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: 60 seconds of intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery
Description: 60 seconds of intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: 60 seconds of intervention
Study: NCT05755100

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: I MOVE!+UP
Description: An individual psychotherapy that integrates behavioral weight management with evidence-based psychotherapy for PTSD (Cognitive Processing Therapy) for up to 6 months, augmented with evidence-based psychiatric and weight management medication management.
Study: NCT05657795

Intervention type: DEVICE
Group type: OTHER
Intervention: Closed-loop automated oxygen control (Oxygenie, SLE6000)
Description: The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
Study: NCT06612879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm.
Study: NCT05158153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ORKID Bundled Intervention
Description: During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure \> 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure \< 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 160 mg oral furosemide twice daily to be taken every day at home
Study: NCT06674486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)
Description: For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)
Description: For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
Study: NCT06673628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Lenvatinib
Description: One course is fixed at 21 days, and the length of course is not extended or shortened.~Participants receive 200 mg of pembrolizumab injection intravenously over approximately 30 minutes on day 1 of each course, and take 20 mg of lenvatinib capsules orally once daily, preferably at the same time each day.~Treatment with pembrolizumab and lenvatinib will be continued for up to 35 courses unless the criteria for termination of protocol treatment are met.
Study: NCT06588257

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Non-infectious adjuvanted recombinant nonavalent HPV vaccine
Description: Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).
Study: NCT05247619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
Description: Tisleliumab 200mg, Bevacizumab 7.5mg/kg, Paclitaxel 175mg/m2, and Cisplatin 50mg/m2 (or Carboplatin AUC5) IV on day 1 of every 21-day cycle.
Study: NCT06588257

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Non-infectious adjuvanted recombinant nonavalent HPV vaccine
Description: Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Non-infectious adjuvanted recombinant nonavalent HPV vaccine
Description: Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Non-infectious adjuvanted recombinant nonavalent HPV vaccine
Description: Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).
Study: NCT06676644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvanted
Description: adjuvanted (aIIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-adjuvanted
Description: non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
Study: NCT06677606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAI block
Description: LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% and 30mg of ketorolac) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.
Study: NCT06676345

Intervention type: PROCEDURE
Intervention: Surgical treatment
Description: Surgical repair of post-infarction mechanical complications (e.g. sutureless or sutured repair for LVFWR, David or Daggett technique for VSR, mitral valve repair or replacement for PMR)

Intervention type: PROCEDURE
Intervention: Percutaneous treatment
Description: Percutaneous approach for the management of post-infarction mechanical complications (e.g. percutaneous closure with device for VSR, Mitraclip for PMR, PIFIT for LVFWR)
Study: NCT06676865

Intervention type: DIAGNOSTIC_TEST
Intervention: the palm print test
Description: The patient's dominant hand was pressed firmly against a blue ink pad, then onto a white sheet of paper without applying body weight. The palm prints were scored as follows:~* Grade 0: All phalangeal areas visible~* Grade 1: Deficiency in the interphalangeal areas of the 4th and 5th digits~* Grade 2: Deficiency in the interphalangeal areas of the 2nd to 5th digits~* Grade 3: Only the tips of the digits visible The palm print test was scored from 0 to 3. Grades 2 and 3 were considered indicators of difficult intubation.
Study: NCT06676956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Order of bronchoscopy procedures for peripheral nodule biopsy
Description: Patient scheduled to undergo peripheral nodule biopsy of the lung under bronchoscopy typically get both a nodule biopsy as well as a linear EBUS of the lymph nodes to assess for any disease spread. This procedure will randomize patients to either getting the peripheral nodule first or linear EBUS of the lymph nodes first and assess overall diagnostic yield as the primary outcome.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Order of bronchoscopy procedures for peripheral nodule biopsy
Description: Patient scheduled to undergo peripheral nodule biopsy of the lung under bronchoscopy typically get both a nodule biopsy as well as a linear EBUS of the lymph nodes to assess for any disease spread. This procedure will randomize patients to either getting the peripheral nodule first or linear EBUS of the lymph nodes first and assess overall diagnostic yield as the primary outcome.
Study: NCT05799963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioMatrix Alpha
Description: Patient will be treated with BioMatrix Alpha
Study: NCT06676371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemiarch replacement
Description: Conventional open hemiarch replacement
Study: NCT04150198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEP/IRM
Description: All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEP/IRM
Description: All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEP/IRM
Description: All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
Study: NCT06052488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength After Breast Cancer
Description: Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
Study: NCT04714970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shame stimulation
Description: TMS coil vertical to the brain surface, with same protocol as iTBS
Study: NCT05881902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION
Description: A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STANDART CANCER EDUCATİON
Description: The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
Study: NCT06676371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: E-vita® Open Neo; Artivion
Description: E-vita® Open Neo is a hybrid stent graft system for aortic arch and descending thoracic aorta repair with Frozen Elephant Trunk Technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraflex Hybrid; Terumo
Description: The Thoraflex Hybrid is a device system designed to repair a weakened and bulging section (aneurysm) and/or a tear in the lining (dissection) of the aorta behind the heart (aortic arch). The system includes a polyester graft section that reinforces a weakened section of the blood vessel, a connected stented section (nitinol wire frame on polyester graft material) that holds the artery open, and a delivery catheter that is used to place the device. The polyester graft and stented sections are coated with a protein substance taken from animal body parts (gelatin) to seal the implant and prevent blood from leaking out.
Study: NCT06676462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy with visionPRO
Description: Video laryngoscopy to be performed using the visionPRO (HEINE® Optotechnick, Gilching, Germany) during intubation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video laryngoscopy with Glidescope
Description: Video laryngoscopy to be performed using theGlideScope (Verathon Inc., Bothell, USA) during intubation.
Study: NCT06676774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.
Study: NCT05571722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Injection
Description: Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Injection
Description: Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
Study: NCT04901741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: 400 mg per week as continous infusion until progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: 400 mg per week as continous infusion until progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
Study: NCT06020339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The midwife-led continuous care model (MLCC)
Description: Continuity of midwife-led care has been defined as care in which the midwife is the leading professional in the planning, organization and delivery of care given to a woman from the initial assessment of the pregnant woman to the postpartum period.~ELSBM; It is the same midwife or midwife group providing the care and counseling needed by the woman during pregnancy, childbirth and postpartum period. In this care model, the midwife is the leading health care specialist who is responsible for planning and arranging the care given to women in the antenatal, natal and postnatal period. MLCC is woman-centered and is based on the idea that pregnancy and childbirth are normal life events.~This care model includes education, counseling and care according to the needs of the woman. It promotes vaginal delivery as a normal process and advocates minimal interventions. Continuity of midwifery-led care is associated with superior outcomes for women and infants than other models of care.
Study: NCT06389188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RHB Group
Description: The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RHB Group
Description: The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks
Study: NCT05312424

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low GG
Description: 150 mg GG

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High GG
Description: 300 mg GG
Study: NCT04976777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Updated DEX PS DDS Applicator
Description: Intravitreal Administration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Approved DEX PS DDS Applicator
Description: Intravitreal administration
Study: NCT05785689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: To reduce postoperative agitation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bolus saline
Study: NCT06465732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: the active comparator arm receive dupilumab only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: the active comparator arm receive dupilumab only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: the experimental arm receive dupilumab plus tofacitinib.
Study: NCT04976777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.7 mg in a solid polymer drug delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.7 mg in a solid polymer drug delivery system
Study: NCT06010680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]SHR2554
Description: Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
Study: NCT04669249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCare
Description: PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
Study: NCT05707871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes
Description: SPECTRUM cigarettes have varying amount of nicotine content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual brand of Cigarettes
Description: Usual Brand of Cigarettes